07:00 , Oct 3, 2011 |  BC Week In Review  |  Company News

Novagali, Santen deal

Santen will acquire fellow ophthalmic company Novagali for €6.15 per share, or about €100 million ($134.2 million). The price is a 71% premium to Novagali's close of €3.59 on Sept. 27, before the deal was...
00:14 , Sep 29, 2011 |  BC Extra  |  Company News

Santen to acquire Novagali

Santen Pharmaceutical Co. Ltd. (Tokyo:4536; Osaka:4536) will acquire fellow ophthalmic company Novagali Pharma S.A. (Euronext:NOVA) for EUR 6.15 per share, or about EUR 100 million ($134.2 million). The price is a 71% premium to Novagali's...
07:00 , Sep 12, 2011 |  BC Week In Review  |  Clinical News

Catioprost: Phase II data

A single-blind, U.S. Phase II trial in 105 patients with glaucoma or ocular hypertension and ocular surface disease showed that once-daily Catioprost was non-inferior to Travatan Z travoprost in reducing mean IOP at 3 months....
07:00 , Apr 25, 2011 |  BC Week In Review  |  Clinical News

Catioprost: Completed Phase II enrollment

Novagali completed enrollment of 105 patients with glaucoma or ocular hypertension and ocular surface disease in a single-blind, U.S. Phase II trial comparing Catioprost vs. Travatan Z travoprost. The Alcon Inc. division of Novartis AG...
08:00 , Jan 3, 2011 |  BC Week In Review  |  Clinical News

Catioprost: Phase II started

Novagali began a single-blind, U.S Phase II trial to compare Catioprost vs. Travatan Z travoprost in 100 patients with glaucoma or ocular hypertension and ocular surface disease. Alcon Inc. (NYSE:ACL, Hunenberg, Switzerland) markets Travatan Z....
07:00 , Jul 26, 2010 |  BioCentury  |  Finance

Bear out of Hibernation

Dov Pharmaceutical Inc. has been slowing dying for a long time, but its neglected assets are now back in play in newco Euthymics Bioscience Inc. , which VCs financed with $24 million in a tranched...
07:00 , Mar 16, 2009 |  BC Week In Review  |  Clinical News

Novagali preclinical data

In a toxicological rabbit model, Nova21027 did not induce obvious toxicity to the ocular surface compared with conventional formulations of prostaglandin analogs. The study compared the 0.005% latanoprost in cationic emulsion with benzalkonium chloride (BAC)-containing...